Table 1.
Patients’ characteristics.
| Bevacizumab-Treated Patients | Control Group | p-Value | |
|---|---|---|---|
| Patient n° | 10 | 10 | |
| Age (median, range) | 54 years (42y–67y) | 48.5 years (45y–71y) | 0.845 |
| ECOG Performance Status | |||
| 1 | 1/10 (10%) | 2/10 (20%) | |
| 2 | 7/10 (70%) | 5/10 (50%) | |
| 3 | 2/10 (20%) | 3/10 (30%) | |
| Tumor Grading at primary diagnosis | 0.628 | ||
| I | 0 | 0 | |
| II | 4/10 (40%) | 2/10 (20%) | |
| III | 6/10 (60%) | 8/10 (80%) | |
| FIGO stage at primary diagnosis | 1 | ||
| IIIC | 8/10 (80%) | 7/10 (70%) | |
| IV | 2/10 (20%) | 3/10 (30%) | |
| PDS NACT | 5/10 (50%) 5/10 (50%) |
6/10 (60%) 4/10 (40%) |
1 |
| RT at first surgery (cm) | 1 | ||
| =0 | 9/10 (90%) | 8/10 (80%) | |
| >0 | 1/10 (10%) | 2/10 (20%) | |
| Type of recurrence at the time of blood sampling | 0.061 | ||
| Intraperitoneal only | 7/10 (70%) | 5/10 (50%) | |
| intraperitoneal + retroperitoneal | 1/10 (10%) | 2/10 (20%) | |
| widespread | 2/10 (20%) | 3/10 (30%) |
NACT: Neoadjuvant chemotherapy; PDS: Primary Debulking Surgery; RT: Residual Tumor.